CAR-T Cells Therapy for Patients With Autoimmune Diseases
Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART